This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Cidara Therapeutics (20D0) Stock Overview

Operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. More details

20D0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 64.6% below our estimate of its fair value

Revenue is forecast to grow 62.44% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

20D0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Cidara Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cidara Therapeutics
Historical stock prices
Current Share Price	US$183.00
52 Week High	US$194.00
52 Week Low	US$13.70
Beta	1.53
1 Month Change	-1.08%
3 Month Change	115.29%
1 Year Change	626.19%
3 Year Change	969.93%
5 Year Change	370.92%
Change since IPO	-33.97%

Recent updates

Shareholder Returns

	20D0	DE Biotechs	DE Market
7D	0%	-2.5%	0.7%
1Y	626.2%	-7.6%	2.2%

Return vs Industry: 20D0 exceeded the German Biotechs industry which returned -30.1% over the past year.

Return vs Market: 20D0 exceeded the German Market which returned 14.5% over the past year.

Price Volatility

Is 20D0's price volatile compared to industry and market?
20D0 volatility
20D0 Average Weekly Movement	31.0%
Biotechs Industry Average Movement	8.9%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: 20D0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 20D0's weekly volatility has increased from 24% to 31% over the past year.

About the Company

Founded	Employees	CEO	Website
2012	38	Jeff Stein	www.cidara.com

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.

Cidara Therapeutics, Inc. Fundamentals Summary

How do Cidara Therapeutics's earnings and revenue compare to its market cap?
20D0 fundamental statistics
Market cap	€5.96b
Earnings (TTM)	-€158.08m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-37.7x

P/E Ratio

Is 20D0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
20D0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$131.82m
Gross Profit	-US$131.82m
Other Expenses	US$52.98m
Earnings	-US$184.80m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-5.87
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 20D0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/06 03:25
End of Day Share Price	2026/01/06 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cidara Therapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Timothy Chiang	BTIG
Eun Kyung Yang	Jefferies LLC
Kevin DeGeeter	Ladenburg Thalmann & Company

This company is no longer active

Cidara Therapeutics (20D0) Stock Overview

Rewards

Risk Analysis

Cidara Therapeutics, Inc. Competitors

Hamlet BioPharma

Biotest

Biotest GmbH KGaA

Formycon

Price History & Performance

Recent News & Updates

Merck Sharp & Dohme LLC completed the acquisition of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics Reaches Target Enrollment of Phase 3 Anchor Trial Evaluating Cd388 for Prevention of Seasonal Influenza in High-Risk Populations

Merck Sharp & Dohme LLC entered into an Agreement and Plan of Merger to acquire Cidara Therapeutics, Inc. (NasdaqCM:CDTX) for $7 billion.

Cidara Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Cidara Therapeutics, Inc. Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics Reaches Target Enrollment of Phase 3 Anchor Trial Evaluating Cd388 for Prevention of Seasonal Influenza in High-Risk Populations

Merck Sharp & Dohme LLC entered into an Agreement and Plan of Merger to acquire Cidara Therapeutics, Inc. (NasdaqCM:CDTX) for $7 billion.

Cidara Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Cidara Therapeutics, Inc. Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Cidara Therapeutics, Inc. Announces Expanded and Accelerated Phase 3 Plan for CD388, A Non-Vaccine Preventative of Seasonal Influenza

Cidara Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Growth Index

Cidara Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350.000024 million.

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

Cidara Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $70 million.

Cidara Therapeutics, Inc. Announces Promotion of Executives, Effective May 1, 2025

Cidara Therapeutics, Inc. to Report Q1, 2025 Results on May 08, 2025

Cidara Therapeutics, Inc., Annual General Meeting, Jun 18, 2025

Cidara Therapeutics, Inc. Announces Two Presentations on Cd388 in Influenza At International Conference on Antiviral Research 2025

Cidara Therapeutics Announces Publication of Cd388 Preclinical Data in Nature Microbiology

Cidara Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective February 24, 2025

Cidara Therapeutics, Inc. Announces Management Changes

Cidara Therapeutics, Inc. Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors

Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members

Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388

Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

New minor risk - Profitability

Forecast to breakeven in 2025

Third quarter 2023 earnings released: US$0.091 loss per share (vs US$0.17 profit in 3Q 2022)

Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

New major risk - Financial position

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

New minor risk - Profitability

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.14 loss in 2Q 2022)

Forecast to breakeven in 2025

Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection)

New major risk - Share price stability

Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

New minor risk - Market cap size

Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform

First quarter 2023 earnings released: EPS: US$0.032 (vs US$0.27 loss in 1Q 2022)

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.81 loss in FY 2021)

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform

Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.17 (vs US$0.36 loss in 3Q 2021)

Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market

Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza

Cidara Therapeutics, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.18 profit in 2Q 2021)